Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Publication year range
1.
Pharm. pract. (Granada, Internet) ; 21(4)oct.- dec. 2023. tab, mapas
Article in English | IBECS | ID: ibc-229984

ABSTRACT

Background: The reverse logistics of medicines consists of the logistical procedure of collection, transport, storage, treatment and final disposal of post-consumer or expired waste. Medicines can be toxic to the environment and affect the health of citizens of the territory. Community pharmacies, as a health facility, play a key role in this process. Objectives: Define the spatial analysis and cases of reverse logistics of medicines in community pharmacies in Brazil. Methods: This is a cross-sectional study, and the research covered the medicines collected by 400 community pharmacies in the period from 2020 to 2022. To obtain the data, the medicines were collected, weighed, segregated and the weight released on a dedicated waste management platform. All regions of Brazil subject to georeferencing were processed using the free software Geographic Information System (QGIS). Data were expressed as median and range or as frequency of occurrence. Chi-square t-test and Fisher's exact test were used to compare variables. The accepted significance level was 5%. Results: Of the five existing regions in Brazil, only three had records of reverse medication logistics. 4,519.74 Kg of products were collected, and the North region of Brazil was responsible for 69.1% of the collection. In the spatial analysis, it was possible to perceive a difference between the areas of concentration of the RDL, that is, locations where collections were carried out in the period from 2020 to 2022. Conclusion: The present study preliminarily analyzed the reverse logistics of medicines in Brazil. The data obtained can contribute to the knowledge of this area and to the strengthening of the process. Thus, these places must exercise a task force for the educational process of the population about the risks of incorrect disposal of medicines and that this could harm the environment, economic aspects of society, food and the entire context that involves health and well-being. of citizens (AU)


Subject(s)
Humans , Community Pharmacy Services , Reverse Logistics , Spatial Analysis , Cross-Sectional Studies , Retrospective Studies
2.
Pharm. pract. (Granada, Internet) ; 21(3): 1-5, jul.-sep. 2023. tab
Article in English | IBECS | ID: ibc-226167

ABSTRACT

Background: Immunochromatographic rapid tests in pharmacies allow the discovery of specific antibodies against SARS-CoV-2 or viral antigens and provide a broader and more effective screening of the virus. However, in many countries, this process is still not well defined. In this sense, the perception of pharmacists about these screening practices presents an overview of how the service is being carried out in the country. Objective: This study was to evaluate the performance of rapid immunochromatographic tests and their clinical results in community pharmacies in northern Brazil. Method: A retrospective study was carried out between May 2020 and December 2021 in community pharmacies in the northern region of Brazil. Participants were 18 years of age or older, of both sexes, who spontaneously sought the SARS-CoV-2 rapid testing service at pharmacies located in the municipality of Belem and who had had close contact with the virus or symptoms infection-related. Data were expressed as median and range or as frequency of occurrence. Chi-square t-test and Fisher’s exact test were used to compare variables. The accepted significance level was 5%. This study was approved by the Research Ethics Committee (number: 4,865,206). Results: A total of 78,849 patients were recruited into the study. Most patients, 37,847 (48%), were tested antibody positive for SARS-CoV-2. There were no severe signs and symptoms of the disease. The results showed the great demand for carrying out the rapid test in pharmacies and these places could contribute to the understanding of this health establishment, to curb the speed of SARS-CoV-2 dissemination. (AU)


Subject(s)
Humans , Male , Female , Young Adult , Adult , Middle Aged , Aged , Aged, 80 and over , Pandemics , Coronavirus Infections/epidemiology , Coronavirus Infections/diagnosis , Pharmacies , Retrospective Studies , Brazil , Severe acute respiratory syndrome-related coronavirus , Pharmaceutical Services , Clinical Laboratory Techniques
3.
Pathog Glob Health ; 114(7): 388-392, 2020 10.
Article in English | MEDLINE | ID: mdl-32705964

ABSTRACT

Primaquine is still the first-line drug to eliminate hypnozoites of Plasmodium vivax. The therapeutic efficacy is related to the total dose administered. In several endemic areas, the drug is administered for children in an age-based regimen, which can lead to inadequate exposure, increasing the rates of recurrence of the infection. The present study aims to describe the mg/kg total dose of primaquine administered to children for treatment for vivax malaria when an age-based regimen is used and to measure the plasma concentrations of primaquine and carboxyprimaquine. A total of 85 children were included in the study. The total dose of primaquine administered based on mg/kg had a median value of 3.22 mg/kg. The percentage of patients with a total dose below the required dose of 3.5 mg/kg was 55.75%. The median primaquine maximum concentration was 94 ng/ml. For carboxy-primaquine, the median maximum concentration was 375 ng/ml. The results suggest that age-based dosing regimens likely lead to substantial under-dosing of primaquine, which is evident in the youngest children and is reflected in decreased levels of primaquine and carboxy-primaquine in plasma samples 13.


Subject(s)
Antimalarials/administration & dosage , Drug Administration Schedule , Malaria, Vivax , Primaquine/administration & dosage , Adolescent , Antimalarials/therapeutic use , Child , Child, Preschool , Humans , Infant , Malaria, Vivax/drug therapy , Plasmodium vivax , Primaquine/therapeutic use
4.
Malar J ; 18(1): 439, 2019 Dec 21.
Article in English | MEDLINE | ID: mdl-31864358

ABSTRACT

BACKGROUND: A total dose of chloroquine of 25 mg/kg is recommended by the World Health Organization (WHO) to treat malaria by Plasmodium vivax. In several endemic areas, including the Brazilian Amazon basin, anti-malarial drugs are dispensed in small plastic bags at a dosing regimen based on age. This practice can lead to suboptimal dosing of the drug, which can impact treatment outcomes. The aim of the present study was to estimate the extent of sub-dosing of chloroquine in children and adolescents with vivax malaria using an age-based dose regimen, in addition to investigating the influence of age on the plasma concentrations of chloroquine and desethylchloroquine. METHODS: A study of cases was conducted with male patients with a confirmed infection by P. vivax, ages 2 to 14 years, using a combined regimen of chloroquine and primaquine. Height, weight and body surface area were determined at admission on the study. The total dose of chloroquine administered was estimated based on the weight and on the body surface area of the study patients. Chloroquine and desethylchloroquine were measured on Day 7 in each patient included in the study by a high-performance liquid chromatographic method with fluorescence detection. RESULTS: A total of 81 patients were enrolled and completed the study. The median age was 9 years (2-14 years). All patients presented negative blood smears at 42 days follow-up. The total dose of chloroquine ranged from 13.1 to 38.1 mg/kg. The percentage of patients with a total dose of the drug below 25 mg/kg ranged from 29.4 to 63.6%. The total dose of chloroquine administered based on BSA ranged from 387 to 1079 mg/m2, increasing with age. Plasma chloroquine concentrations ranged from 107 to 420 ng/ml, increasing with age. For desethylchloroquine, the plasma concentrations ranged from 167 to 390 ng/ml, with similar values among age-groups. CONCLUSION: The data demonstrated the widespread exposure of children and adolescents to suboptimal doses of chloroquine in the endemic area investigated.


Subject(s)
Antimalarials/administration & dosage , Chloroquine/administration & dosage , Malaria, Vivax/prevention & control , Adolescent , Brazil , Child , Child, Preschool , Chloroquine/analogs & derivatives , Chloroquine/blood , Chromatography, High Pressure Liquid , Dose-Response Relationship, Drug , Humans , Male , Plasmodium vivax/drug effects
5.
Rev Inst Med Trop Sao Paulo ; 60: e66, 2018 Oct 25.
Article in English | MEDLINE | ID: mdl-30379233

ABSTRACT

In the last two years, a substantial increase in the number of malaria vivax cases has occurred in the Brazilian Amazon basin. The adequate exposure of hypnozoites to primaquine is a matter of interest as these dormant forms are responsible for the maintenance or even the increase of malaria burden in endemic areas. The aim of this study was to estimate the levels of primaquine and carboxyprimaquine in whole blood samples of patients with P. vivax treated with chloroquine and an abbreviated regimen of primaquine (0.5 mg/kg/d for 7 days), with adequate clinical and parasitological outcomes after 180 days of follow-up. A total of 40 male patients met the criteria for inclusion in the study. Primaquine and carboxyprimaquine were measured by high-performance liquid chromatography. The levels of primaquine in whole blood samples ranged from 40-238 ng/mL, 42-196 ng/mL and 42-150 ng/mL on days 1, 3 and 7. The levels of carboxyprimaquine in whole blood samples ranged from 87-234 ng/mL, 96-252 ng/mL and 74-448 ng/mL on days 1, 3 and 7. These data provide a reliable estimation of exposure of the infecting parasite to primaquine. Based on the regional pattern of relapse, the estimated blood levels of primaquine can be considered effective against hypnozoites of the local circulating strains of P. vivax.


Subject(s)
Antimalarials/blood , Malaria, Vivax/blood , Malaria, Vivax/drug therapy , Primaquine/analogs & derivatives , Primaquine/blood , Adult , Antimalarials/administration & dosage , Brazil , Chromatography, High Pressure Liquid , Drug Administration Schedule , Drug Therapy, Combination , Follow-Up Studies , Humans , Male , Primaquine/administration & dosage , Prospective Studies
6.
Rev. para. med ; 28(3)jul.-set. 2014. tab
Article in Portuguese | LILACS-Express | LILACS | ID: lil-737141

ABSTRACT

Objetivo: determinar os níveis de glutationa reduzida em pacientes com malária por Plasmodium vivax não complicada no decorrer do tratamento com cloroquina e primaquina. Método: estudo quantitativo longitudinal de casos em 62 sujeitos do sexo masculino com malária por Plasmodium vivax no estado do Pará de dezembro de 2010 a dezembro de 2012. A glutationa reduzida foi determinada por espectrofotometria visível, que baseou-se na sua capacidade de reduzir ácido -5,5-ditiobis-2-nitrobenzóico (DTNB) e ácido nitrobenzóico (TNB). Resultado: o nivel médio de glutationa reduzida em pacientes com malária (2,03+-1, rumol/ml) foi significativamente inferior aquele de voluntários saudáveis (3,42 +- 1,36 umol/ml). No decorrer do tratamento, houve diminuição significativa dos níveis de glutationa reduzida> Conclusão: Os níveis de glutationa reduzida em pacientes com malária por P. vivax antes da introdução da quimioterapia, foram significativamente inferiores aqueles de voluntários saudáveis pareados por idade. A administração de antimaláricos foi acompanhada pela redução dos níveis de glutationa reduzida.


Objective: determine the reduced glutathione levels in patients with uncomplicated malaria by Plasmodium vivax during the treatment with chloroquine and primaquine. Method: A longitudinal quantitative

SELECTION OF CITATIONS
SEARCH DETAIL
...